Mesoblast Corporate Overview - CEO Message to AGM
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from Mesoblast
- Response to ASX price query
- Positive Disc Repair Results Using Mesoblast Stem Cells
- New Japanese Regenerative Medicine Legislation
- MSBs Registration Plans for GVHD Cell Product in Japan
- MSB Receives $4.3M Pipeline Funds from Australian Government
Later from Mesoblast
- Clearance for First Phase 2 Clinical Trial for Eye Diseases
- FDA Clearance for Phase 2 Clinical Trial in Type 2 Diabetes
- FDA Clearance for Phase 3 Bone Marrow Transplant Trial
- First European Trial for Heart Attack Treatment Cleared
- First Minimally Invasive Procedure for Lumbar Disc Repair
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast